epithelial cells. These cysts keep increasing in size and number and gradually cause renal failure in about 50% of the ADPKD patients by the age of 60 years (1) . Data from Chronic Kidney Disease (CKD) Registry of India reveals that ADPKD accounts for 2.5% of CKD in India (2) . The severity of the disease, the age of onset of end stage renal disease (ESRD) and the extra-renal manifestations vary widely among the affected individuals. In 85% of the patients, a mutation is observed in PKD1 gene, while the rest have mutations in PKD2 gene (3) . Generally, the mean age of ESRD in PKD1 linked patients is 54 years and in PKD2 linked patients is 70 years (4) The VEGF gene is located on chromosome 6 (6p21.1). It is highly polymorphic, especially in the promoter, 5'-untranslated and 3'-untranslated regions (9) . Some of these polymorphisms (-2578C>A, -1154G>A, -634G/C and +936C/T) have been related to varying VEGF protein expression and serum VEGFA levels (10, 11) , in various diseases, such as renal cell carcinomas (12), recurrent pregnancy loss (13) , breast cancer (9) and lung cancer (14) . The polymorphisms, -2578C>A (rs699947) and -1154G>A (rs1570360) have been documented to influence the progression of disease in ADPKD patients (15) . The two VEGF polymorphisms had a minor allele frequency (MAF)≥ 0.05, ascertained from South Asian (SAS) population in 1000 Genomes Phase 3 data (http:// phase3browser.1000genomes.org/index.html).
In the present study we analyzed the distribution of -2578 >A and -1154G >A promoter polymorphisms of VEGF gene in patients of ADPKD and controls, and also examined their association with the progression to chronic kidney disease (CKD) in North Indians.
Materials and methods

Study Population
The study was carried out on 223 subjects comprising 123 unrelated ADPKD cases and 100 healthy, unrelated controls (without any disease, including renal, enrolled from among those visiting the hospital). The patients of ADPKD were enrolled from the Nephrology Department of Sir Ganga Ram 
Genotyping of VEGF promoter polymorphisms
DNA was extracted from peripheral blood (19) and amplified using previously published primers (13) . PCR was carried out followed by restriction 
Statistical analysis
Differences in the VEGF genotypes, allele frequencies and haplotypes among the four defined groups were analyzed using Fisher's exact test or
Chi-square (χ2) test. Hardy-Weinberg equilibrium (HWE) was evaluated for both cases and controls using Chi-square test and the goodness-of-fit test.
The strength of association between genotypes, allele frequencies and haplotypes were measured using odds ratio (OR) (20) . SNPStats was used to study different models of inheritance (21) . Linkage disequilibrium and haplotypes were established using SHEsis software (22) and statistical analysis was done using microsoft excel and statistical package for social sciences program (SPSS) software Version 21. All P-values<0.05 were considered as statistically significant.
Results
The mean age of the patients with ADPKD Further evaluation was carried out under different models of inheritance (co-dominant, dominant, recessive and over-dominant) for both polymorphisms (23) . Table 2 
Linkage disequilibrium and haplotype analysis
Haplotypes were constructed for the two polymorphisms (-2578C>A and -1154G>A) using SHEsis software (22) (Table 3 ).
Logistic regression analysis was used to assess the relation between CKD progression and other independent variables among the ADPKD patients sub-groups 2 (advanced CKD) and 3 (early CKD).
It was observed that the male gender (OR, 3.67;
95%CI, 1.6-8.3; P= 0.002) and a positive family history (OR, 3.12; 95%CI, 0.135-0.762; P= 0.010) of the disease were associated with a 3-fold increased risk of CKD progression. Table 4 describes the age at respective CKD stages and the genotype present in ADPKD patient sub-groups for the present study. A statistically significant difference in the age at respective CKD stage was not observed with regard to different genotypes.
Discussion
The results observed in the present casecontrol study demonstrate that the VEGF polymorphism may accelerate the progression of 8% vs. 18%, respectively; P=0.002) (Table 3) .
However, with respect to cases in early and advanced-CKD stages, the difference between the genotypes and the haplotypes were not significant. Chinese (14) and Japanese end stage renal disease patients (29) . These discrepancies could be due to the ethnicity difference or may result from different impacts of VEGF polymorphisms in disease pathophysiology. In conclusion, the present study 
